Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income: 2013-2025

Historic Net Income for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to -$183.5 million.

  • KalVista Pharmaceuticals' Net Income rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$183.5 million for FY2025, which is 44.86% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Net Income of -$183.5 million as of FY2025, which was down 44.86% from -$126.6 million recorded in FY2024.
  • KalVista Pharmaceuticals' Net Income's 5-year high stood at -$82.3 million during FY2021, with a 5-year trough of -$183.5 million in FY2025.
  • In the last 3 years, KalVista Pharmaceuticals' Net Income had a median value of -$126.6 million in 2024 and averaged -$134.3 million.
  • Data for KalVista Pharmaceuticals' Net Income shows a maximum YoY crashed of 182.80% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Net Income stood at -$82.3 million in 2021, then remained steady at -$82.3 million in 2022, then fell by 12.83% to -$92.9 million in 2023, then slumped by 36.31% to -$126.6 million in 2024, then slumped by 44.86% to -$183.5 million in 2025.